Commentary Outrage of the Month: In Face of Raging Opioid Addiction Crisis, FDA Fuels the Fire January 1, 2019
Letters, Testimony & Filings Letter to the FDA Commissioner Refuting Claims Made in His Public Statement Justifying the Approval of Sufentanil Sublingual Tablets (Dsuvia) December 11, 2018
Fact Sheets & Backgrounders Op-Ed in The Washington Post Regarding the FDA’s Approval of Sufentanil Sublingual Tablets: The FDA Made the Wrong Call on This Powerful, New Opioid November 16, 2018
Press Releases White House Must Cut Prices, Expand Access to Opioid Overdose Antidote October 23, 2018
Letters, Testimony & Filings Letter to the FDA Urging the Agency Not to Approve the New Drug Application for Sufentanil Sublingual Tablets, a Super-Potent Opioid October 18, 2018
Letters, Testimony & Filings Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee Regarding Sublingual Sufentanil Tablets October 12, 2018
Commentary Outrage of the Month: Pharma’s Price Gouging Forces Rationing of Lifesaving Opioid Overdose Antidote June 1, 2018